Neutropenic Sepsis Guideline
|
|
- Erik Holt
- 5 years ago
- Views:
Transcription
1 Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt treatment with intravenous (IV) antibiotics IMMEDIATELY ON PRESENTATION to anywhere within the hospital. Patients who are neutropenic following anti-cancer treatment may initially appear well. However, infections may progress rapidly to shock or death, especially when due to gram-negative bacilli. This guideline exists to provide assistance to admitting clinicians when faced with a case of suspected infection and neutropenia in both solid tumour oncology and haemato-oncology. If there is clinical suspicion of neutropenic sepsis in existing inpatients, they should be treated within 1 hour of clinical onset, as defined by baseline observations, Early Warning Score (EWS) or clinical suspicion. Neutropenic Sepsis Neutropenic sepsis can be diagnosed in patients who present with a neutrophil count of 1.0x10 9 /L and/or a fever. NB fever may not be present in some infected neutropenic patients. Infection should be suspected in any patient who is feeling generally unwell following chemotherapy. Fever Fever is a single oral temperature of 38⁰C. Diagnose neutropenic sepsis in patients having anti-cancer treatment whose neutrophil count is 1.0x10 9 /L and who have a temperature 38⁰C, a temperature of 37.5⁰C on two occasions recorded 1 hour apart, or other signs or symptoms consistent with clinically significant sepsis. NB fever may not be present in some infected neutropenic patients. Infection should be suspected in any patient who is feeling generally unwell following chemotherapy. Sepsis in non-neutropenic haem-oncology patients Patients who are severely immunocompromised due to primary haematological disorders or recent chemotherapy (e.g. bone marrow transplant / conditioning) may not have a neutrophils 1.0x10 9 /L at time of testing. These patients are at risk of similar infective complications and should be managed under the supervision of haematology / oncology team. There is a 24 hour on call service These guidelines may be used to treat septic episodes in this group with all cases discussed with the haematology / oncology team. These guidelines are designed to complement the pan-london neutropenic sepsis management guidelines available online
2 Neutropenic Sepsis Guideline Suspected or proven infection in a neutropenic patient is a medical emergency and is an indication for immediate assessment and immediate treatment with intravenous (IV) (within 1 hour of presentation) Inclusion: Patients with a) Suspected/confirmed neutropenic sepsis, b) Patient receiving chemotherapy in last 3 months or has bone marrow failure due to primary haematological disorder [Do not wait for FBC before initiating treatment] Check if the patient has: - Penicillin allergy - if severe IgE mediated reaction (e.g. anaphylaxis, angioedema or urticarial) discuss treatment with microbiology No 1 st Line therapy: Piperacillin /tazobactam IV 4.5g QDS plus Amikacin IV 15mg/kg stat* (*7.5mg/kg stat if known CrCl <40ml/min or AKI present) Do not delay dosing waiting for exact body wt / CrCl Yes Alternative therapy: Meropenem IV 1g TDS (penicillin allergy cross sensitivity reported at 1%; avoid in anaphylaxis) Or Beta-Lactam Free option: Discuss with microbiology If a patient has: - recent history of MRSA - a long line present (e.g. PICC/Hickman) - severe mucositis Add a glycopeptide: e.g. Vancomycin IV or Teicoplanin IV (dosing guide) Common Modifications To Initial Empirical Treatment In Neutropenic Patients Head, ear, eye, nose and throat Vesicular or ulcerative lesions consider HSV and VZV treatment Sinus tenderness or nasal ulcerative lesions suspect fungal infection e.g. aspergillus or zygomycetes such as mucor. Gastrointestinal Retrosternal symptoms consider endoscopy likely organisms include candida or HSV. In severely immunocompromised patients CMV should be considered Acute abdominal pains seek surgical advice Diarrhoea consider Clostridium difficile (refer to local guidelines) Respiratory Community acquired pneumonia with atypical presentation consider Azithromycin PO / clarithromycin IV Viral symptoms - Send nose and throat swabs for respiratory virus PCR / consider treatment Investigate for PCR / CMV / mycobacteria / PCP anyone who is neutropenic post transplant / chemo needs consideration of PCP. Central nervous system infections Suspected meningitis/encephalitis: Meropenem 2g IV TDS and consider adding Aciclovir 10mg/kg TDS IV Discuss all cases with microbiology Known Carbapenem resistant organism (CRO) / Vancomycin resistant enterococcus (VRE) colonised Discuss with microbiology
3 1. Continuing assessment The patient should be assessed at least every 2 hours in the initial period and daily with daily FBC and U&E. LFT and CRP tested at least three times weekly. If there is any change in clinical condition or rising early warning scores then prompt reassessment should take place. Fluid balance and urine output need to be monitored hourly Reassessment Daily Day 2 (48 hours) If white cell counts are improving, neutrophils are greater than 0.5 x 10 9 /l, and no microbiology evidence of infection then complete a five day course of antibiotics. Consider IV-to-PO switch / stopping aminoglycoside No clinical deterioration: The current antibiotic regimen should be continued for a further 24 hours then review antibiotics. Continue amikacin therapy (if part of empiric prescription - see TDM/dosing in local guidelines) Clinical deterioration: A full clinical assessment should take place and further clinical investigation, including repeat blood and urine cultures, should be arranged as indicated. Continue amikacin therapy (if part of empiric prescription - see TDM/dosing in local guidelines) Consider non-bacterial causes. A senior physician should decide if initiation of antifungal or antiviral treatment may be appropriate at this stage. Review antibiotic therapy to consider including a glycopeptide. Day 3 (72 hours) Review Sensitivities (if available) note: amikacin may be de-escalated to gentamicin where sensitivities known If white cell counts are improving, neutrophils are greater than 0.5 x 10 9 /l, and no microbiology evidence of infection then complete course of antibiotics. Consider IV-to-PO switch / stopping aminoglycoside A full clinical assessment should take place and further clinical investigation, including repeat blood and urine cultures, should be arranged as indicated. Consider non bacterial causes. A senior physician should decide if initiation of antifungal or antiviral treatment may be appropriate at this stage. Review antibiotic therapy to consider including a glycopeptide. Second line antimicrobials (carbapenem) plus a glycopeptide may be considered.
4 Day 4 (96 hours) If white cell counts are improving and neutrophils are greater than 0.5 x 10 9 /l then consider switching to IV antibiotics to oral antibiotics to complete course / and stopping aminoglycoside If the patient remains febrile and neutropenic after four days of appropriate antibacterial therapy then an antifungal drug should be considered at this stage (see below for dosing of antifungal therapy). Arrange imaging CT chest, liver and spleen. Consider CT of other regions including the CNS as symptoms/signs dictate. Consider galactomannan and B-D-Glucan testing for fungal infection. An antiviral should usually only be considered if there is microbiological evidence or in the case of cutaneous Herpes or Varicella infections. Day 5+ If afebrile for more than 48 hours, the physician can consider changing to broad spectrum oral therapy especially if the neutrophil count is recovering (>0.5 x 10 9 /l). Consider an antifungal if not already commenced. Continue to repeat cultures and consider further imaging of chest and abdomen as clinically indicated. Consider galactomannan and B-D-Glucan for fungal infection. Possible Cytomegalovirus (CMV) infection / reactivation should also be considered send quantitative CMV PCR and discuss with micro- virology or HIV consultant Duration of Antibiotics (IV / PO) Patients with neutrophil count 0.5 x 10 9 /l After review may stop antibiotics if patient has been apyrexial for 3 days if: a) cultures indicate organism eradicated b) all sites of infection have resolved c) patient free of signs and symptoms d) falling acute phase reactants e.g. CRP On discussion with the relevant consultant Patients with neutrophil count <0.5 x 10 9 /l Low risk and above factors a) to d) met, Stop antibiotics when patient has been afebrile for 5 days High risk (e.g. if patient has mucositis, ulcers, bleeding points, iv-catheter site infection present or if invasive procedures or ablative chemotherapy pending) Continue antibiotics so that patient receives at least 10 days treatment in total or until neutrophils 0.5 x 10 9 /l
5 Anti-fungal agents The decision to commence antifungal treatment must be made on the clinical evidence. However there is rarely a positive microbiological confirmation of a fungal organism. Evidence suggests that up to one third of neutropenic patients who remain pyrexial for seven days may have a fungal infection. Any decision to start therapy should be made in consultation with a senior haematologist, usually the consultant. An attempt to establish a diagnosis may be made by high resolution CT scan of the chest and possibly liver and in selected patients bronchoscopy with lavage or nasal sinus washings. It is appropriate to consider these investigations when starting antifungal therapy. Invasive aspergillosis can occur in severely immunocompromised patients and empiric antifungal therapy should target aspergillus infection. Antifungal therapy should be based on the nature of the patient s illness, degree of immunosuppression, taking into account the potential side effects and interactions with other medication Empirical anti-fungal therapy Clinical / Patient risk factors for mould infections (e.g. aspergillosis) Low risk of mould infection (non-respiratory source / negative HRCT) Significant respiratory symptoms, other reason for high suspicion of moulds (e.g. aspergillosis), or prolonged neutropenia (>7 days) First line Review antifungal therapy based on imaging and antigen results Caspofungin IV 70mg stat then 50mg OD (<80kg) or 70mg ( 80kg) Note: Echinocandins are static against moulds (including aspergillis) and should only be used where mould infection is NOT suspected / a risk. Discuss with consultant Voriconazole IV / PO (see dosing below) Potent cytochrome P450 interactions; check for drug interactions Or AmBisome IV 3mg/kg daily OD (IV Test dose on initial infusion) 1.2. Targeted anti-fungal therapy Candida species Empiric Rx Blood cultures/deep Sites Alternative Rx Contra-indicated or failure of 1st line therapy Antifungal Route Dosing Duration Caspofungi n AmBisome (liposomal amphoteric in) Step down therapy for Candida sp sensitive strains / line tip positive and removed in stable patient Fluconazol e IV/PO* Aspergillosis - Proven invasive / high suspicion IV IV 70mg stat; then 50mg/day (<80kg) or 70mg/day ( 80kg) 3mg/kg OD (IV Test dose on initial infusion) 400mg OD Discuss with microbiology/ haematology Uncomplicated line infection, complete 14 days post line removal Note: The oral bioavailability of fluconazole and voriconazole is greater than 90%. Empiric Rx Voriconazole IV/PO* See dosing information below Alternative Rx AmBisome (liposomal amphotericin) Other (including moulds) IV 3mg/kg OD (IV Test dose on initial infusion) Discuss each case with microbiology Discuss with micro
6 1.3. Antifungal drug information Liposomal amphotericin B AmBisome There is the largest base of evidence to show that amphotericin has activity against a broad range of fungi. However, amphotericin B has an unacceptable level of toxicity and therefore a lipid formulation should be used. It is licensed for empirical use in suspected fungal infections. It should be used as 1st line where liver involvement with fungi is proven or suspected. A test dose of 1mg (over 15 minutes) must be given as part of the first dose and patients observed for 30 minutes. Side effects: Hypokalaemia: Almost inevitable with treatment and potassium supplements should be considered. Magnesium levels should be monitored at least three times per week. Infusion related reactions: Include pyrexia and rigors. These usually diminish with continued therapy. Patients may require premedication with paracetamol 1g orally and chlorphenamine 10mg IV. Steroid cover should generally be avoided where possible in immunocompromised patients. The reactions may be so severe that a different agent is required. Contact microbiology to discuss alternative options. Nephrotoxicity: Well recognised and rises in serum creatinine may require a reduction in dose or changing to different antifungal therapy. Ensure the patient is well hydrated prior to infusion to reduce nephrotoxicity Abnormal liver function test: Usually mild and not clinically relevant. Severe disturbance may require discontinuation of therapy Echinocandins Caspofungin Dose: 70 mg stat dose, then continue daily at 70mg 80 kg or 50mg <80kg ONCE daily No dose adjustment for patients with renal failure of any degree (renal function should be monitored) Monitor liver function; Avoid in liver impairment where possible; a dose reduction to 35mg/day advised in Child-Pugh score C
7 Azoles Voriconazole Voriconazole can be used as a 1st line treatment for invasive aspergillosis. It is also licensed for the treatment of resistant Candida and Aspergillus infection so may be used where patients are intolerant of the above treatments (discuss with Consultant / microbiologist). It also has the advantage that it is available in an oral form and therefore treatment can be continued as an outpatient. IV dose: 6mg/kg 12 hourly for 2 doses then 4mg/kg bd Oral dose: >40kg 400mg 12 hourly for 2 doses then 200mg bd, <40kg 200mg bd then 100mg bd Side effects: The drug is metabolised by cytochrome P450 liver enzymes. Therefore it has a large number of drug interactions. Check on possible interactions before starting the drug. Visual disturbances: Common and usually clinically insignificant and transient. Abnormal liver function test: May require cessation of the drug GI disturbances: Common. Posaconazole Used on the advice of microbiology or consultant haematologist/oncologist for prevention / treatment of aspergillosis / moulds PO dose: 300mg tablets ONCE daily (liquid not recommended as 1 st line due to unpredictable absorption)
Antimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationHigh risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR
DERBY TEACHING HOSPITALS NHS FOUNDATION TRUST Prophylaxis, diagnosis and treatment of invasive fungal infections in oncology/haematology patients with prolonged neutropenia. High risk neutropenic patient
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationCARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS
CARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS This Care Pathway has been developed by a multidisciplinary team. It
More informationA Care Pathway exists for the management of neutropenic fever. Copies of the care pathway document are available in EAU, A&E, Deanesly and CHU.
Subject: Neutropenic Fever Guideline for Junior Doctors Date of Implementation: January 2010 Date of Review: January 2012 Director Responsible for Implementation and Review: Policy location: Consultant
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationPAGL Inclusion Approved at January 2017 PGC
Guideline for the prophylaxis and treatment of fungal infections in Haematology patients 1. Introduction PAGL Inclusion Approved at January 2017 PGC Haematology, CHUGGS June 2016 This guideline sets out
More informationMATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)
MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationChildren who are neutropenic and unwell, even if normothermic, should be assumed to have infection and be treated appropriately.
PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY Purpose: This document is intended as a guide to the investigation and management of children presenting in Salisbury District Hospital with suspected neutropenic
More informationR-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.
R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg
More informationProtocol for the Management of Neutropenic Sepsis in Adult Patients P
Protocol for the Management of Neutropenic Sepsis in Adult Patients P Version 2 Date April 2015 Review Date April 2016 Author Rachel Onions Change Approver Acute Oncology Team UHMBT. Version 2. CHANGE
More informationHAEMATOLOGY ANTIFUNGAL POLICY
HAEMATOLOGY ANTIFUNGAL POLICY PROPHYLAXIS Primary Prophylaxis Patient Group Patients receiving intensive remissioninduction chemotherapy for Acute Leukaemia (excluding patients receiving vinca alkaloids)
More informationGuideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation
Guideline for the Management of Fever Neutropenia in Children with Cancer /or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive
More informationAntifungal therapy guidelines
Background Invasive fungal infections (IFI) can cause significant morbidity and mortality among patients with haematological malignancies. There is good evidence for the use of antifungal prophylaxis in
More informationPAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY
PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY Purpose: This document is intended as a guide to the investigation and management of children presenting in Salisbury District Hospital with suspected neutropenic
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationGASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT
GASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT Name & Title Of Author: Dr Linda Jewes, Consultant Microbiologist Date Amended: December 2016 Approved by Committee/Group: Drugs & Therapeutics
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationLung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationManagement of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy.
Management of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy. Written by: Dr K Gajee, Consultant Microbiologist Date: June 2017 Approved by: Drugs & Therapeutics Committee
More informationScottish Childrens Cancer MSN CYPC Febrile Neutropenia Guideline December 2013, Version 1
Scottish Childrens Cancer MSN CYPC Febrile Neutropenia Guideline December 2013, Version 1 NICE guidance 2012 is taken into account but this document includes some alternative recommendations. This is due
More informationNEUTROPENIC SEPSIS IN ADULT PATIENTS. Consultant Clinical Oncologist CLINICAL GUIDELINE
Lancashire Teaching Hospitals NHS Foundation Trust NEUTROPENIC SEPSIS IN ADULT PATIENTS KEY WORDS (To assist in searching for the Guideline on the Intranet suggested minimum 10 words ) REF NO: Neutropenic
More informationLung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationDr. Arghya Samanta PG-3 Department of Pediatrics
Dr. Arghya Samanta PG-3 Department of Pediatrics A 3 year old male K/C/O B-cell Acute lymphoblastic leukemia Undergoing induction phase of chemotherapy On day 23 of induction Presented with - high grade
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationFebrile Neutropenia (Or Suspected) Patient Management (ADULT) Procedure Cairns and Hinterland Hospital and Health Service
Procedure Document Number CoC-Proc-Clin-307-V3-01/17 Febrile Neutropenia (Or Suspected) Patient Management (ADULT) Procedure Cairns and Hinterland Hospital and Health Service Custodian/Review Officer:
More informationECMM Excellence Centers Quality Audit
ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationAdult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.
AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough
More informationEMPIRICAL PRESCRIBING GUIDELINES FOR SYSTEMIC FUNGAL INFECTIONS IN ADULTS - HH (1)/CL(G)/651/13
Hampshire Hospitals NHS Foundation Trust Empirical Antifungal Prescribing Guidelines [INSERT UNIQUE POLICY IDENTIFIER] Due for latest review on January 2015. CHECK THE INTRANET FOR LATEST VERSION EMPIRICAL
More informationMANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSP There are no translations available. MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
More informationANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS
ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS Version 4.0 Date ratified February 2009 Review date February 2011 Ratified by Authors Consultation Evidence
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationPILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS
PILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS RATIONALE: It is increasingly being recognised that not all neutropenic patients have the same risk of complications during episodes
More informationUPDATE ON FEBRILE NEUTROPENIA
UPDATE ON FEBRILE NEUTROPENIA Clinical approach and management Dr.Shafiq A. Alimad Head of medical department at university of science and technology hospital YICID 15-December-2014 INTRODUCTION Cancer
More informationObinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case
Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available
More informationNeutropenic Fever. CID 2011; 52 (4):e56-e93
Neutropenic Fever www.idsociety.org CID 2011; 52 (4):e56-e93 Definitions Fever: Single oral temperature of 101 F (38.3 C) Temperature 100.4 F (38.0 C) over 1 hour Neutropenia: ANC < 500 cells/mm 3 Expected
More informationR-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative
R-GemOx INDICATION Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative TREATMENT INTENT Disease modification PRE-ASSESSMENT 1. Ensure histology
More informationProtocol for Management of Neutropenic Sepsis in Adult Patients within the First 24 hours of Presentation
Protocol for Management of Neutropenic Sepsis in Adult Patients within the First 24 hours of Version One Date of Publication: May 2010 Original Author(s): Carole Connor Nurse Consultant Dr Beth Harrison
More informationFebrile Neutropenia (Or Suspected) in Adults - Patient Management Procedure Cairns and Hinterland Hospital and Health Service.
Procedure Document Number CHHSD-CoC-Proc-Clin-307-V4-02/20 Febrile Neutropenia (Or Suspected) in Adults - Patient Management Procedure Cairns and Hinterland Hospital and Health Service Custodian/Review
More informationX M/ (R) Dose adjusted (DA)-EPOCH-R
X M/ (R) adjusted (DA)-EPOCH-R Indication High-risk CD20+ diffuse large B cell lymphoma especially C-MYC and BCL-2 activated (i.e. double hit lymphoma) and mediastinal sclerosing (thymic) large B cell
More informationNeutropenic Fever 1 InpatientPediatric Treatment
Neutropenic Fever InpatientPediatric Treatment (Hematologic Cancers and Stem Cell Patients) te: This algorithm should not be used for patients receiving CAR cell therapy. Page of 8 Patient presents with
More informationCisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer
Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Page 1 of 5 Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastrooesophageal junction. Patient
More informationOxaliplatin and Gemcitabine
Oxaliplatin and Gemcitabine Indication Palliative treatment for relapsed metastatic seminoma, non seminoma or combined tumours. ICD-10 codes Codes pre-fixed with C38, C48, C56, C62, C63, C75.3. Regimen
More informationViral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected
More informationTitle Management of Fever and Neutropenia (Neutropenic Sepsis) in Paediatric Oncology Patients presenting to NDDH Guidelines. Author s job title
Document Control Title Management of Fever and Neutropenia (Neutropenic Sepsis) in Paediatric Oncology Patients presenting to NDDH Guidelines Author Consultant Microbiologist Consultant Paediatrician Consultant
More informationCLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN ADULT CANCER PATIENTS (this guideline excludes haematology patients)
CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN ADULT CANCER PATIENTS (this guideline excludes haematology patients) 1. Aim/Purpose of this Guideline 1.1. Systemic cancer treatments and immunological
More information4.05 Protocol name: Alemtuzumab (MabCampath ), intravenous
4.05 Protocol name: (MabCampath ), intravenous Indication Treatment of CLL refractory to fludarabine (either primary i.e. 17p deletion, or secondary i.e. following previous fludarabine treatment), without
More informationCisplatin Vinorelbine (Oral) therapy +/- radiotherapy
1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer
More informationInfective Endocarditis Empirical therapy Antibiotic Guidelines. Contents
Infective Endocarditis Empirical therapy Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Group Additional author(s): as above Authors Division: Division of Clinical
More informationVIP (Etoposide, Ifosfamide and Cisplatin)
VIP (Etoposide, Ifosfamide and Cisplatin) Indication First line treatment for metastatic seminoma, non seminoma or combined tumours where bleomycin is contra-indicated. Usually used for patients with intermediate
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma. TREATMENT INTENT Palliative or curative depending on context.
More informationReducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway
Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway Dr Alex Williams, Oncology Specialty Doctor. Cheltenham General Hospital Oncology Centre
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A AAP. See American Academy of Pediatrics (AAP) Acyclovir dosing in infants, 185 187 American Academy of Pediatrics (AAP) COFN of, 199 204 Amphotericin
More informationECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic
Page 1 of 5 As an alternative to ECF: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer; peri-operative use in oesophageal or gastric cancer; adenocarcinoma of unknown primary
More informationTrust Guideline for the Use of Antifungals in Adults
For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager: Supported
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationAilyn T. Isais-Agdeppa, MD*, Lulu Bravo, MD*
A FIVE-YEAR RETROSPECTIVE STUDY ON THE COMMON MICROBIAL ISOLATES AND SENSITIVITY PATTERN ON BLOOD CULTURE OF PEDIATRIC CANCER PATIENTS ADMITTED AT THE PHILIPPINE GENERAL HOSPITAL FOR FEBRILE NEUTROPENIA
More informationNeutropenic Sepsis Acute General Management and Support. Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology
Neutropenic Sepsis Acute General Management and Support Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology Who Am I? I am A Medical Oncologist (MCCN) Site specialist
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More information(R) CODOX M / (R) IVAC
(R) CODOX M / (R) IVAC Indication Burkitt's or Burkitt's-like lymphoma, especially those with 1 or more of the following poor risk criteria: - Raised LDH level - WHO performance status 2-4 - Ann Arbor
More informationUrology and Urinary Tract Infections in Adults
Urology and Urinary Tract Infections in Adults Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationHospital-acquired Pneumonia
Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationFEBRILE NEUTROPENIA CURRENT GUIDELINES FOR CHILDREN Alia Zaidi, MD. St. Jude International Outreach Program
SIOP PODC Supportive Care Education (ICON 2016) Presentation Date: 23 rd January 2016 Recording Link at www.cure4kids.org: https://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p25oti35nt7
More informationNote: There are other bendamustine protocols, ensure this is the correct one for a given patient.
INDICATIONS 1 st line treatment for follicular lymphoma with FLIPI score 2 or higher: (NICE TA513- BLUETEQ required) Rituximab refractory follicular lymphoma (progression on R-chemo, R-maintenance or within
More informationFungal Infection Pre-Infusion Data
Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode
More informationFungal Infections in Neutropenic Hematological Disorders
Fungal Infections in Neutropenic Hematological Disorders 23 Dr Farah Jijina 24 Fungal Infections in Neutropenic Hematological Disorders 25 Dr Farah Jijina 26 Fungal Infections in Neutropenic Hematological
More informationCisplatin / Paclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual
More informationChoc septique. Frédéric Pène
Choc septique Frédéric Pène Réanimation Médicale, Hôpital Cochin, AP-HP Université Paris Descartes Institut Cochin, Inserm U1016, CNRS UMR-8104, Département 3i No conflict of interest A 54 y.o. male patient
More informationCHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX
CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationPOLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF LOWER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: The Drugs & Therapeutics Committee Date: July 2018 Implementation
More informationLung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION
More informationMICROBIOLOGICAL TESTING IN PICU
MICROBIOLOGICAL TESTING IN PICU This is a guideline for the taking of microbiological samples in PICU to diagnose or exclude infection. The diagnosis of infection requires: Ruling out non-infectious causes
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationHOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?
HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? EORTC IFICG START Look for Help? MORTALITYASSOCIATED WITH INVASIVE ASPERGILLOSIS Lin et al. Clin Infect Dis 2001;32:358 100 % 50 n = 178 0 0 60 120
More informationR-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01
West of Scotland Cancer Network Chemotherapy Protocol R-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01 Indication B cell Chronic Lymphocytic Leukaemia First line therapy in patients under 70 years of
More informationCarboplatin / Gemcitabine Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously
More informationCD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated
INDICATION CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated TREATMENT INTENT Curative or Disease Modification. PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationNorth Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance)
North Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance) Introduction OPAT services provide intravenous (IV) antibiotics to patients
More informationGUIDELINES FOR THE MANAGEMENT AND PREVENTION OF INFECTION IN ONCOLOGY PATIENTS (Including Immunisation Guidelines)
GUIDELINES FOR THE MANAGEMENT AND PREVENTION OF INFECTION IN ONCOLOGY PATIENTS (Including Immunisation Guidelines) 1. MANAGEMENT OF PYREXIA IN ONCOLOGY PATIENTS 2. ANTIBIOTIC LEVEL MONITORING 3. CENTRAL
More informationComparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia
Comparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia I. Malik ( National Cancer lnsititute, Karachi ) Shaharyar (, Department of Radiotherapy
More informationReady to answer the questions?
파워포인트문서의제목 Reference 1. IDSA GUIDELINES. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America.
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationMICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS
When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing
More informationFever. National Pediatric Nighttime Curriculum Written by Debbie Sakai, M.D. Institution: Lucile Packard Children s Hospital
Fever National Pediatric Nighttime Curriculum Written by Debbie Sakai, M.D. Institution: Lucile Packard Children s Hospital Case 1 4-month-old well-appearing girl admitted for croup and respiratory distress.
More information